EATG » Resistance

Resistance

CROI 2019: One in six South Africans drug resistant before starting HIV treatment

One in six people not on treatment in a large South African household survey already had drug-resistant HIV and more than half of those on treatment had resistance to at…

CROI 2019: Genotypic profile and phenotypic susceptibility to temsavir in multidrug-resistant HIV

Fostemsavir, a prodrug of the investigational attachment inhibitor temsavir, is currently under evaluation for treatment-experienced patients with limited treatment options. In a new study, investigators set out to characterize the…

CROI 2019: PrEP use in persons with undetected HIV infections contributes to resistance

With antimicrobial resistance at the top of the World Health Organization’s top 10 global health threats of 2019, it’s only natural that resistance is also at top of mind for…

HIV i-Base: HIV Treatment Bulletin, 22 February 2019

HIV Treatment Bulletin (HTB) is a community publication produced by HIV i-Base. This issue of HTB includes a range of short articles and reports in the relative lull before the…

Antiretroviral resistance testing in people with HIV may not be beneficial

Antiretroviral therapy (ART) drug resistance testing may not benefit people who have HIV in terms of mortality risk or disease progression but may improve virologic outcomes in patients who have…

Effect of HIV Pretreatment Drug Resistance on Virologic Outcomes

Dual-class pretreatment drug resistance to a first-line tenofovir/emtricitabine/efavirenz regimen may be associated with poorer virologic suppression, according to a study recently published in Clinical Infectious Diseases. Resulting in a 36% decline in the…

A New Pathway of HIV-2 Integrase Strand-Transfer Inhibitor Resistance

A new integrase inhibitors resistance pathway has been identified in people infected with HIV-2, rendering isolates that are highly resistant to raltegravir and elvitegravir and moderately resistant to dolutegravir and…

Ibalizumab effective for multidrug-resistant HIV-1 infection

In March 2018, the US Food and Drug Administration (FDA) approved ibalizumab (Trogarzo) for the treatment of multidrug-resistant HIV-1 infection in heavily treatment-experienced adults failing their current antiretroviral regimen.1 This…

Focus on resistance to HIV offers insight into how to fight the virus

Of the 40 million people around the world infected with HIV, less than one per cent have immune systems strong enough to suppress the virus for extended periods of time.…

Drug resistance accumulates fast in people with low but detectable viral loads, Kenyan study finds

Finding poses challenge to current global treatment guidelines A study measuring HIV drug resistance at two timepoints in Kenyan patients on second-line, protease inhibitor-based regimens has found very high levels…

1 2 3 7